InvestorsHub Logo
Followers 46
Posts 3422
Boards Moderated 0
Alias Born 10/15/2013

Re: noretreat post# 778

Wednesday, 12/19/2018 8:55:35 AM

Wednesday, December 19, 2018 8:55:35 AM

Post# of 1085
"Following review of data from all 2,425 patients in the BETonMACE clinical trial, the DSMB concluded the study safe and recommended that we continue per protocol. We are now accruing the final events – to yield at least 250 pre-specified MACE events – prior to study completion," stated Dr. Michael Sweeney, M.D., Senior Vice President of Clinical Development.